- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02032251
Reduction of Sperm DNA Fragmentation by Oral Ginger
Reduction of Sperm DNA Fragmentation by Oral Ginger (Zingiberofficinale) Extract Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sperm DNA fragmentation is known to affect male fertility. Previous findings have suggested the implication of oxidative stress in the etiology of this pathological condition. The present study was designed to find out DNA fragmentation in ejaculated spermatozoa can be reduced by oral treatment with Ginger extract. 71 men with unexplained or Idiopathic infertility were randomized between a Ginger treatment (500 milligram daily for 3months) group and a placebo group.
Sperm DNA fragmentation was evaluated by Terminal deoxyribonucleotidyltransferase-mediated dUTP nick-end labeling assay (TUNEL) before and after treatment. No differences in basic sperm parameters were found between the Ginger treatment and the placebo group before or after treatment. However, the percentage of DNA-fragmented spermatozoa was markedly reduced (P< .005) in the Ginger treatment group after the treatment as compared with the pretreatment values). No difference in the pretreatment and post treatment incidence of sperm DNA fragmentation was observed in the placebo group. These data show that sperm DNA damage can be efficiently treated with oral Ginger extract administered during a relatively short time period.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Royan Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- men with idiopathic infertility or unexplained
Exclusion Criteria:
- history of varicocele, genitourinary inflammation or infection
- history of cigarette smoking.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ginger
The patients with infertility that underwent oral administration of ginger.
|
Oral administration of ginger in patients with infertility.
Other Names:
|
|
Placebo Comparator: Placebo
The patients with infertility that receive placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sperm DNA fragmentation
Time Frame: 3 months
|
Evaluation the percent of the reduction of sperm DNA fragmentation 3 months after ginger administration.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
male hormones
Time Frame: 3months
|
Evaluation the effect of ginger on male hormones 3 months after oral administration.
|
3months
|
|
sperm count
Time Frame: 3 months
|
Evaluation the ginger on sperm count 3 months after oral administration.
|
3 months
|
|
sperm motility
Time Frame: 3 months
|
Evaluation the effect of ginger on sperm motility 3 months after oral administration.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ali DaliriHampa, MD, Department of Andrology, Reproductive Biomedicine Center, Royan Institute for Reproductive Biomedicine
- Study Director: Eyed Jalil Hosseini, MD, Department of Andrology, Reproductive Biomedicine Center, Royan Institute for Reproductive Biomedicine
- Principal Investigator: Hani Department of Andrology, Reproductive Biomedicine Center, Roya, MSc, Department of Andrology, Reproductive Biomedicine Center, Royan Institute for Reproductive Biomedicine
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- royan-Emb-017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Viable BiosciencesEnrolling by invitationInfertility (IVF Patients) | Infertility Assisted Reproductive TechnologyUnited States
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Medipol UniversityNot yet recruitingMale Infertility | Unexplained Infertility | Sperm DNA Fragmentation
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of